J Immunother Cancer February 2023 PMID 36796877

Regulatory implications of ctDNA in immuno-oncology for solid tumors.

Paz J Vellanki, Soma Ghosh, Anand Pathak, Michael J Fusco, Erik W Bloomquist, Shenghui Tang, Harpreet Singh, Reena Philip, Richard Pazdur, Julia A Beaver

Download social card

Mentions

Peak: 27 in Feb 2023

across 3 sources since Feb 2023

Extended reach

88,705

potential audience

Total likes

Video views

143

Mentions per month

Feb 2023 – Nov 2023

Where it's discussed

X / Twitter32 posts
News2 articles
YouTube1 videos

AI synopsis

What people are saying

Several discussions emphasize the significance of ctDNA in advancing immuno-oncology, with phrases like 'regulatory implications' and mentions of the FDA underscore the potential impact on regulatory decisions. The tone reflects a mix of curiosity and professional interest, as seen in references to specific authors and research series, which indicates engagement with the detailed scientific and regulatory aspects of the publication.

AgreementModerate agreement

Most posts acknowledge the importance and relevance of ctDNA in immuno-oncology, showing general support for the article's focus on regulatory implications.

InterestHigh interest

Discussion around regulatory challenges, clinical applications, and regulatory bodies like the FDA indicate high interest levels among the posters.

EngagementModerate engagement

The posts refer to specific authors, research series, and methods, suggesting moderate engagement with the topic's details.

ImpactModerate impact

The emphasis on regulatory implications and potential for improved cancer management reflects a perception that the article could influence clinical practice and policy.

Abstract in brief

The use of circulating tumor DNA (ctDNA) is becoming more important in cancer treatment, especially for diagnosing and managing solid tumors, and it’s helping to make clinical trials more precise by identifying patients who are more likely to benefit from certain therapies.
The US FDA has approved several ctDNA-based tests for targeted cancer therapies, and these tests are also being developed for immunotherapy, especially to detect minimal residual disease (MRD) in early-stage cancers to prevent metastasis.
Before ctDNA can be fully used in regulatory decisions, there needs to be better standardization of testing methods and more clinical research to confirm its role as a reliable biomarker for predicting treatment success or failure.

Read the full abstract

All mentions

Regulatory Impact of ctDNA in Immuno-Oncology for Solid Tumors

Circulating tumor DNA (ctDNA) is increasingly crucial in cancer diagnosis and management, aiding clinical trial precision and early detection of residual disease to prevent metastasis.

BMJ Group · Feb 23, 2023 143 views

Martín Angel

@Martin_AngelMD · X

RT @AndresFCardonaZ: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/vvrLeVJqzi

Nov 14, 2023 · 2 shares · 2,453 followers View post →

Suzanne MacMahon

@SuzanneMacmahon · X

RT @AndresFCardonaZ: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/vvrLeVJqzi

Nov 14, 2023 · 2 shares · 165 followers View post →

Andres F. Cardona

@AndresFCardonaZ · X

Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/vvrLeVJqzi

Nov 14, 2023 · 8 likes · 2 shares · 8,826 followers View post →

Kauhsik Samaddar

@kaushik_s130973 · X

RT @4baseCare: #ResearchThursday This week’s #ResearchThursday paper discusses the regulatory implications of ctDNA in immuno-oncology for…

Jul 6, 2023 · 1 share · 14 followers View post →

4baseCare

@4baseCare · X

Jul 6, 2023 · 1 like · 1 share · 396 followers View post →

IC-ONC Global

@IC_ONC · X

RT @FDAOncology: Regulatory implications of ctDNA in immuno-oncology for solid tumors. First author @PazVellanki, last author @DrJuliaBeave…

Mar 5, 2023 · 7 shares · 550 followers View post →

Crying Wolf

@OncologyCompany · X

RT @FDAOncology: Regulatory implications of ctDNA in immuno-oncology for solid tumors. First author @PazVellanki, last author @DrJuliaBeave…

Feb 24, 2023 · 7 shares · 1,318 followers View post →

Jeevan Puthiamadathil

@jeevanpmd · X

RT @FDAOncology: Regulatory implications of ctDNA in immuno-oncology for solid tumors. First author @PazVellanki, last author @DrJuliaBeave…

Feb 24, 2023 · 7 shares · 81 followers View post →

OncoViews

@OncoViews · X

RT @FDAOncology: Regulatory implications of ctDNA in immuno-oncology for solid tumors. First author @PazVellanki, last author @DrJuliaBeave…

Feb 24, 2023 · 7 shares · 1,852 followers View post →

tiago

@Contadotuiter · X

RT @FDAOncology: Regulatory implications of ctDNA in immuno-oncology for solid tumors. First author @PazVellanki, last author @DrJuliaBeave…

Feb 23, 2023 · 7 shares · 15 followers View post →

George Papadopoulos

@Emerald_CG · X

RT @FDAOncology: Regulatory implications of ctDNA in immuno-oncology for solid tumors. First author @PazVellanki, last author @DrJuliaBeave…

Feb 23, 2023 · 7 shares · 1,087 followers View post →

Scott E Delacroix Jr M.D.

@UroCancer · X

RT @FDAOncology: Regulatory implications of ctDNA in immuno-oncology for solid tumors. First author @PazVellanki, last author @DrJuliaBeave…

Feb 23, 2023 · 7 shares · 1,798 followers View post →

FDA Oncology

@FDAOncology · X

Regulatory implications of ctDNA in immuno-oncology for solid tumors. First author @PazVellanki, last author @DrJuliaBeaver #OCEPublications https://t.co/2WvfBdJTj6 https://t.co/ZitCL5kSo7

Feb 23, 2023 · 16 likes · 7 shares · 40,301 followers View post →

Molecular OncologyLab

@MolecularOncLab · X

RT @MolecularOncLab: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/tiqva9a9RH @FDAOncology @PazVella…

Feb 22, 2023 · 4 shares · 578 followers View post →

Christian Barreto-Vargas

@ChristianDavid2 · X

RT @jitcancer: New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki…

Feb 19, 2023 · 14 shares · 150 followers View post →

Elad Sharon

@EladSharonMD · X

RT @jitcancer: New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki…

Feb 18, 2023 · 14 shares · 3,839 followers View post →

Molecular OncologyLab

@MolecularOncLab · X

RT @jitcancer: New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki…

Feb 18, 2023 · 14 shares · 578 followers View post →

Herbert Loong, MBBS, FASCO

@herbloong · X

RT @jitcancer: New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki…

Feb 18, 2023 · 14 shares · 4,381 followers View post →

Soo-Ryum (Stew) Yang MD

@sooryumyang · X

RT @jitcancer: New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki…

Feb 18, 2023 · 14 shares · 500 followers View post →

Igor Kiss

@Igor_Kiss_ · X

RT @jitcancer: New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki…

Feb 18, 2023 · 14 shares · 80 followers View post →

Antonio Torres

@viniciu_antonio · X

RT @jitcancer: New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki…

Feb 18, 2023 · 14 shares · 341 followers View post →

Teresa Amaral, MD, PhD

@TeresaSAmaral · X

RT @jitcancer: New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki…

Feb 18, 2023 · 14 shares · 1,855 followers View post →

Taxiarchis Botsis

@TaxiarchisB · X

RT @jitcancer: New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki…

Feb 17, 2023 · 14 shares · 33 followers View post →

Taxiarchis Botsis

@TaxiarchisB · X

RT @MolecularOncLab: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/tiqva9a9RH @FDAOncology @PazVella…

Feb 17, 2023 · 4 shares · 33 followers View post →

Johns Hopkins Molecular Tumor Board

@Hopkins_MTB · X

RT @MolecularOncLab: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/tiqva9a9RH @FDAOncology @PazVella…

Feb 17, 2023 · 4 shares · 405 followers View post →

Johns Hopkins Molecular Tumor Board

@Hopkins_MTB · X

RT @jitcancer: New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki…

Feb 17, 2023 · 14 shares · 405 followers View post →

Elsa Anagnostou

@ValsamoA · X

RT @MolecularOncLab: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/tiqva9a9RH @FDAOncology @PazVella…

Feb 17, 2023 · 4 shares · 1,703 followers View post →

Molecular OncologyLab

@MolecularOncLab · X

Feb 17, 2023 · 6 likes · 4 shares · 578 followers View post →

Pat Adams

@PathologyPat · X

Regulatory implications of ctDNA in immuno-oncology for solid tumors | Journal for ImmunoTherapy of Cancer https://t.co/bc504Yitwi

Feb 17, 2023 · 2 likes · 1,511 followers View post →

Elshaddai White, PhD

@BlkBoiScientist · X

RT @jitcancer: New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki…

Feb 17, 2023 · 14 shares · 1,198 followers View post →

Elsa Anagnostou

@ValsamoA · X

RT @jitcancer: New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki…

Feb 17, 2023 · 14 shares · 1,703 followers View post →

Journal for ImmunoTherapy of Cancer

@jitcancer · X

New #JITC review: Regulatory implications of ctDNA in immuno-oncology for solid tumors https://t.co/KnmKMVIZFV @PazVellanki @DrJuliaBeaver https://t.co/w0eSkHBvPL

Feb 17, 2023 · 30 likes · 14 shares · 9,304 followers View post →

Regulatory implications of ctDNA in immuno-oncology for solid tumors.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Regulatory Impact of ctDNA in Immuno-Oncology for Solid Tumors